Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Merck Serono Limited, 5 New Square, Bedfont Lakes Business Park, Feltham, Middlesex, TW14 8HA, UK
Campral EC.
| Pharmaceutical Form |
|---|
|
Enterocoated tablets. Campral tablets are white and round with ‘333’ engraved on one side and approximately 10 mm in diameter. |
Each tablet contains acamprosate (I.N.N.) calcium 333.0 mg as the active ingredient.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Acamprosate |
Acamprosate has a chemical structure similar to that of amino acid neuromediators, such as taurine or gamma-amino-butyric acid (GABA), including an acetylation to permit passage across the blood brain barrier. Acamprosate may act by stimulating GABAergic inhibitory neurotransmission and antagonising excitatory aminoacids, particularly glutamate. It is indicated as therapy to maintain abstinence in alcohol-dependent patients. |
| List of Excipients |
|---|
|
Crospovidone (KOLLIDON CL) |
Aluminium/PVC sheets of blisters presented in cartons of 168 tablets.
Merck Serono Limited, 5 New Square, Bedfont Lakes Business Park, Feltham, Middlesex, TW14 8HA, UK
PL 11648/0289
Date of first authorisation: 18 December 1995
Date of latest renewal: 24 October 2007
| Drug | Countries | |
|---|---|---|
| CAMPRAL | Austria, Australia, Canada, Estonia, Spain, Ireland, Netherlands, Poland, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
